


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:




Claims 1 – 7 and 16 – 25 were cancelled previously.

8. (Currently amended) An indolinone compound having a structure set forth in formula (II):



wherein:

- (a) R_{11} - R_{14} are hydrogen;
- (b) R_{15} and R_{16} are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted aryl, or R_{15} and R_{16} taken together with the nitrogen atom to which they are attached form a ring structure selected from the group consisting of a five-membered ~~or six-membered~~ heteroaromatic ring, and a five-membered ~~or six-membered~~ heteroaliphatic ring, ~~a nine-membered fused bicyclic heteroaromatic ring, and a ten-membered fused bicyclic heteroaromatic ring;~~ and
- (c) A is selected from the group consisting of formula (III), (IV), and (V):



wherein:

- (i) R_{19} - R_{25} and R_{27} - R_{31} are hydrogen;
- (ii) R_{17} and R_{18} are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted alkoxy provided that both R_{17} and R_{18} are not hydrogen; and
- (iii) R_{26} is selected from the group consisting of optionally substituted alkyl; or a pharmaceutically acceptable salt thereof.

9. (Currently amended) The compound of claim 8, wherein:

- (i) R₁₅ is hydrogen or alkyl;
- (ii) R₁₆ is hydrogen, alkyl, or phenyl, wherein said phenyl group is optionally substituted with one or two substituents selected from halo or unsubstituted lower alkyl; ~~or R₁₅ and R₁₆ together with the nitrogen to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoquinolin-2-yl ring wherein said rings are optionally substituted with halo or alkyl;~~
- (iii) R₁₇ is hydrogen, methyl, or methoxy;
- (iv) R₁₈ is selected from the group consisting of lower alkoxy substituted with heteroalicyclic; and
- (v) A is group of formula III.

10. (Currently amended) The compound of claim 8, wherein:

- (i) R₁₅ is hydrogen or methyl;
- (ii) R₁₆ is hydrogen, methyl, isopropyl, phenyl, 3-chlorophenyl, or 4-chloro-2-fluorophenyl; ~~or R₁₅ and R₁₆ together with the nitrogen atom to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, 5-bromo-2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoquinolin-2-yl;~~
- (iii) R₁₇ is selected from the group consisting of hydrogen, methyl, and methoxy; and
- (iv) R₁₈ is selected from the group consisting of hydrogen, 2-pyrrolidin-1-yl-ethoxy and 2-morpholin-4-yl-ethoxy;

11. (Currently amended) The compound of claim 8, wherein:

- (i) R₁₅ is hydrogen or alkyl;
- (ii) R₁₆ is hydrogen, alkyl, or phenyl optionally substituted with one or two substituents selected from halo or unsubstituted lower alkyl; ~~or~~
- ~~— (iii) —~~ ~~R₁₅ and R₁₆ together with the nitrogen to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoquinolin-2-yl ring wherein said rings are optionally substituted with halo or alkyl;~~
- (iii) R₂₆ is selected from the group consisting of optionally substituted alkyl; and
- (iv) A is group of formula IV.

12. (Currently amended) The compound of claim 8, wherein:

(i) R₁₅ is hydrogen or methyl;

(ii) R₁₆ is hydrogen, methyl, isopropyl, phenyl, 3-chlorophenyl, or 4-chloro-2-fluorophenyl, or R₁₅ and R₁₆ together with the nitrogen atom to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, 5-bromo-2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoisoquinolin-2-yl; and

(iii) R₂₆ is methyl.

13. (Currently amended) The compound of claim 8, wherein:

(i) R₁₅ is hydrogen or alkyl;

(ii) R₁₆ is hydrogen, alkyl, phenyl optionally substituted with one or two substituents selected from halo or unsubstituted lower alkyl; or R₁₅ and R₁₆ together with the nitrogen to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoisoquinolin-2-yl ring wherein said rings are optionally substituted with halo or alkyl; and

(iii) A is group of formula V.

14. (Currently amended) The compound of claim 8, wherein:

(i) R₁₅ is hydrogen or methyl; and

(ii) R₁₆ is hydrogen, methyl, isopropyl, phenyl, 3-chlorophenyl, or 4-chloro-2-fluorophenyl, or R₁₅ and R₁₆ together with the nitrogen atom to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, 5-bromo-2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoisoquinolin-2-yl; and

(iii) A is group of formula V.

15. (Currently amended) A compound selected from the group consisting of:

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1H-indol-2-ylmethylene]-2,3-dihydro-1H-indole-5-sulfonic acid amide,

3-[5-(2-morpholin-4-yl-ethoxy)-1H-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid amide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1H-indol-2-ylmethylene]-2,3-dihydro-1H-indole-5-sulfonic acid methylamide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid isopropylamide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid phenylamide,

~~5-(2,3-dihydro-indole-1-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-amide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-methyl-amide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid (4-chloro-2-fluoro-phenyl)-amide,

~~5-(3,4-dihydro-2*H*-quinoline-1-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~

~~5-(3,4-dihydro-1*H*-isoquinoline-2-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~

~~5-(5-bromo-2,3-dihydro-indole-1-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid isopropylamide,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid phenylamide,

~~5-(2,3-dihydro-indole-1-sulfonyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-amide,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-methyl-amide,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (4-chloro-2-fluoro-phenyl)-amide,

~~5-(3,4-dihydro-2*H*-quinoline-1-sulfonyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~

~~5-(3,4-dihydro-1*H*-isoquinoline-2-sulfonyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~

~~5-(5-bromo-2,3-dihydro-indole-1-sulfonyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,~~

3-(1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,

3-(2-methyl-1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,

3-(1*H*-indol-5-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,

3-(1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,

3-(2-methyl-1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,

3-(1*H*-indol-5-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,

3-(1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,

3-(2-methyl-1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,

3-(1*H*-indol-5-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,

and 3-(4-methoxy-1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide;

or a pharmaceutically acceptable salt thereof.

REMARKS

Counsel would like to thank Examiners Saeed and Ramsuer for the courtesy of an interview held on July 15, 2003 at the PTO.

Applicants respectfully request reconsideration of the present application in view of the foregoing amendments and in view of the reasons which follow.

Claims 8 – 15 are currently being amended. All of the claims are being amended to remove what the Examiner considers non-elected subject matter.

No claims are being added.

This amendment adds, changes and/or deletes claims in this application. A detailed listing of all claims that are, or were, in the application, irrespective of whether the claim(s) remain under examination in the application, are presented, with an appropriate defined status identifier. After amending the claims as set forth above, claims 8 – 15 are pending in this application.

Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicants hereby petition for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Date 7/22/03

FOLEY & LARDNER
Customer Number: 22428




22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Respectfully submitted,

By 

Beth A. Burrous
Attorney for Applicants
Registration No. 35,087